Condition

Adenocarcinoma (1)

Advanced Gastric Cancer (1)

Advanced Gastroesophageal Adenocarcinoma (1)

First-line Therapy (1)

PDL1 CPS < 5 (1)

Stomach Neoplasm (1)

Overall Status

Completed (2)

Not yet recruiting (2)

Phase

phase 2 (2)

phase 1/phase 2 (1)

phase 3 (1)

Sponsor

Charite University, Berlin, Germany (1)

Chinese PLA General Hospital (1)

Genentech, Inc. (1)

West China Hospital (1)

Collaborator

Chugai Pharmaceutical (1)

Hoffmann-La Roche (1)

Intervention

5-fluorouracil (1)

5-fu, oxaliplatin, leukovorin (flo) (1)

bevacizumab (1)

capecitabine (1)

capeox regimen combined with sintilimab and bevacizumab (1)

capox combined with bevacizumab and tislelizumab (1)

cisplatin (1)

pazopanib (1)

placebo (1)

Study Documents

Intervention Type

drug (3)

combination product (1)

Funder Type

Other (3)

Industry (1)

Study Type

Interventional (4)

AVAGAST

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Stomach Tumor Trial in Chengdu (Capeox regimen combined with Sintilimab and Bevacizumab)

Not yet recruiting

Stomach Neoplasm

Capeox regimen combined with Sintilimab and Bevacizumab

Chengdu, China

Liu Ming

Nov 28, 2022

Advanced Gastroesophageal Adenocarcinoma, First-line Therapy, PDL1 CPS < 5 Trial (CAPOX combined with bevacizumab and

Not yet recruiting

Advanced Gastroesophageal Adenocarcinoma
+2 more

CAPOX combined with bevacizumab and Tislelizumab

(no location specified)

Mar 17, 2022

Advanced Gastric Cancer Trial in Berlin (Pazopanib, 5-FU, Oxaliplatin, Leukovorin (FLO))

Completed

Advanced Gastric Cancer

Pazopanib
5-FU, Oxaliplatin, Leukovorin (FLO)

Berlin, Germany

Charite University medicine

Feb 11, 2019

Adenocarcinoma Trial in United States (Bevacizumab, Capecitabine, Cisplatin)

Completed

Has Results

Adenocarcinoma

Bevacizumab
+4 more

Beverly Hills, California
+12 more

May 16, 2017